Real-World Experience with Ceftolozane-Tazobactam for Multidrug-Resistant Gram-Negative Bacterial Infections-Reference-Cited by-同舟云学术

Real-World Experience with Ceftolozane-Tazobactam for Multidrug-Resistant Gram-Negative Bacterial Infections

Published:2020-03-24 Issue:4 Volume:64 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Jorgensen Sarah C. J.¹,Trinh Trang D.¹²,Zasowski Evan J.¹³,Lagnf Abdalhamid M.¹,Simon Samuel P.⁴⁵,Bhatia Sahil¹,Melvin Sarah M.¹,Steed Molly E.⁶,Finch Natalie A.⁷,Morrisette Taylor¹⁸,Estrada Sandy J.⁹¹⁰,Rosenberg Joshua R.⁴,Davis Susan L.¹¹¹,Rybak Michael J.¹¹²¹³

Affiliation:

1. Anti-Infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan, USA

2. Medication Outcomes Center, Department of Clinical Pharmacy, School of Pharmacy, University of California, San Francisco, San Francisco, California, USA

3. Department of Clinical Sciences, College of Pharmacy, Touro University California, Vallejo, California, USA

4. Brooklyn Hospital, Brooklyn, New York, USA

5. Maimonides Medical Center, Brooklyn, New York, USA

6. Department of Pharmacy Practice, School of Pharmacy, University of Kansas, Kansas City, Kansas, USA

7. Department of Pharmacy, Ben Taub Hospital, Harris Health System, Houston, Texas, USA

8. Department of Pharmacy, University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, Aurora, Colorado, USA

9. Department of Pharmacy, Lee Health, Fort Myers, Florida, USA

10. T2 Biosystems Inc., Lexington, Massachusetts, USA

11. Department of Pharmacy, Henry Ford Hospital, Detroit, Michigan, USA

12. Department of Medicine, Wayne State University, Detroit, Michigan, USA

13. Department of Pharmacy, Detroit Medical Center, Detroit, Michigan, USA

Abstract

Our objective was to describe the prescribing practices, clinical characteristics, and outcomes of patients treated with ceftolozane-tazobactam (C/T) for multidrug-resistant (MDR) Gram-negative infections. This was a multicenter, retrospective, cohort study at eight U.S. medical centers (2015 to 2019). Inclusion criteria were age ≥18 years and receipt of C/T (≥72 hours) for suspected or confirmed MDR Gram-negative infection. The primary efficacy outcome, evaluated among patients with MDR Pseudomonas aeruginosa infections, was composite clinical failure, namely, 30-day all-cause mortality, 30-day recurrence, and/or failure to resolve or improve infection signs or symptoms after C/T treatment.

Funder

Merck

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.02291-19

Reference46 articles.

1. Impact of multidrug-resistantPseudomonas aeruginosainfection on patient outcomes

2. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States, 2013. U.S. Department of Health and Human Services, Washington DC. https://www.cdc.gov/drugresistance/pdf/ar-threats-2013-508.pdf.

3. Mechanisms of Multidrug Resistance in Acinetobacter Species and Pseudomonas aeruginosa

4. The Effectiveness and Safety of High-Dose Colistin: Prospective Cohort Study

5. Aminoglycosides: Nephrotoxicity

Cited by 42 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Verdict on Vancomycin and Piperacillin/Tazobactam-Associated Nephrotoxicity: Acquittal by Biomarkers or Guilty as Charged?;Current Infectious Disease Reports;2024-01-19

2. Clinical outcomes of intensive care unit patients infected with multidrug-resistant gram-negative bacteria treated with ceftazidime/avibactam and ceftolozane/tazobactam;Brazilian Journal of Microbiology;2023-12-22

3. Hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP) in Canada: treatment update and the role of new IV antimicrobials;Expert Review of Anti-infective Therapy;2023-10-13

4. Multidrug-resistant Pseudomonas aeruginosa: A pathogen with challenging clinical management;Enfermedades infecciosas y microbiologia clinica (English ed.);2023-10

5. Multidrug-resistant Pseudomonas aeruginosa: A pathogen with challenging clinical management;Enfermedades Infecciosas y Microbiología Clínica;2023-10